Zhitong Finance App News, Fu Hong Han Lin (02696) announced that in the first quarter of 2024, the Group will seize its existing first-mover advantage, comprehensively promote the product commercialization process, and continue to build innovative business models and optimize resource allocation. During the reporting period, the Group achieved revenue of approximately RMB 1,349 billion. The results of the two core products sold and promoted in China (excluding Hong Kong, Macao and Taiwan regions, same as below) led by the Group's self-built commercialization team during the reporting period are as follows:

Han Quyou (trastuzumab for injection, European trade name: Zercepac, US trade name: HERCESSI^TM, Han Quyou) is the first domestic trastuzumab independently developed by the Group and approved for marketing. It has also been approved for marketing in Europe and the US. With its differentiated advantages such as 150 mg and 60 mg dual specifications and no preservatives, Han Quyou has benefited more than 180,000 Chinese patients since it went on sale. During the reporting period, Han Quyou achieved sales revenue of approximately RMB 671 million in China.

Hans-type (Slulizumab injection, Hans-type) is the first bioinnovative drug independently developed and approved for marketing by the Group. It is also the world's first first-line anti-PD-1 monoclonal antibody for the treatment of small cell lung cancer. As of the date of this announcement, the marketing registration application (NDA) for Hans-type approval for marketing in China covered microsatellite highly unstable solid tumors, squamous non-small cell lung cancer (SqNSCLC), extensive small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC). The fifth indication non-squamous non-small cell lung cancer (NSCLC) has been accepted. During the reporting period, Hans achieved sales revenue in China of approximately RMB 334 million.

The Group will always be guided by clinical needs, deeply cultivate fields such as oncology and autoimmune diseases, deepen the global strategic layout, promote high-quality product innovation, increase market expansion and international cooperation, and further consolidate Biopharma's commercialization capabilities.